Category Health Policy Watch

“We Must Engage With Industry” – WHO Director Explains Limits On Lobbyists

The engagement of actors such as industry, civil society, philanthropy and academia with the World Health Organization has been a subject of controversy, with some of those actors being potentially able to influence the work of the organisation. A framework for engagement with those stakeholders was agreed two years ago. At last week's Executive Board meeting, the new WHO director general explained that engagement with those actors, and notably industry, is worth the risk, which he said can be managed.

The Top 5 Issues In EU Medicines Policy For 2018 (Including IP)

Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably.

WHO Board Backs Ambitious Work Programme, Sent For Full Membership Approval

The World Health Organization programme of work 2019-2023 is one step closer to being adopted by member states and serving as a guideline for the future vision and mission of the organisation. The Executive Board approved the programme last week and recommended its adoption at the upcoming World Health Assembly. The programme issued by the secretariat in autumn was revised twice, as countries requested amendments.

Importance Of Flu Pandemic Preparedness Confirmed By WHO Board Decision

One hundred years after the great Spanish flu pandemic, World Health Organization members today underlined their satisfaction with the organisation’s framework to get countries best prepared for the next pandemic: The WHO Executive Board agreed on keeping most of the funds coming to the framework for preparedness measures, and a smaller portion for response measures, unless emergency strikes.

New Text Shows Progress Of Negotiation On IP And Access At WHO

The Brazilian ambassador and others this morning at the World Health Organization Executive Board meeting were not going to let go of what seemed to be a delaying tactic by the United States and Japan to postpone agreement on the implementation of measures aimed at facilitating research and development and access to medicines. The WHO Board today is considering a set of streamlined strategic measures on public health, innovation, and intellectual property.

WHO Board Shows Resolve In Tackling Shortages, Access To Medicines, Vaccines

The members of the World Health Organization Executive Board tonight (24 January) agreed to create a roadmap on global shortages of, and access to, medicines and vaccines. WHO members proclaimed the urgent need to address prices and availability of safe and efficient medicines and vaccines, some requesting the recently elected director general of the organisation to help find solutions.

Three New Draft Proposals At WHO: Shortages, Snakebite, Assistive Technology

Three new draft proposals at the World Health Organization Executive Board this week underline the importance of access and affordability, whether it is vaccines and medicines, including antivenoms, or assistive technology. The draft resolutions call on member states as well as the WHO secretariat to urgently take action to facilitate access to products and technologies at affordable prices.